| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 97.53% | Piper Sandler | $11 → $8 | Maintains | Overweight |
| 11/13/2023 | 122.22% | Stephens & Co. | $14 → $9 | Maintains | Overweight |
| 10/24/2023 | 97.53% | Morgan Stanley | $15 → $8 | Maintains | Overweight |
| 10/16/2023 | 171.6% | Piper Sandler | $14 → $11 | Maintains | Overweight |
| 10/12/2023 | 72.84% | UBS | $12 → $7 | Maintains | Buy |
| 08/08/2023 | 270.37% | Morgan Stanley | $16 → $15 | Maintains | Overweight |
| 08/08/2023 | 295.06% | Stephens & Co. | → $16 | Reiterates | Overweight → Overweight |
| 05/10/2023 | 295.06% | Morgan Stanley | $17 → $16 | Maintains | Overweight |
| 03/21/2023 | 295.06% | Stephens & Co. | → $16 | Reiterates | → Overweight |
| 03/08/2023 | 319.75% | Morgan Stanley | $18 → $17 | Maintains | Overweight |
| 11/03/2022 | 369.14% | Capital One | → $19 | Initiates Coverage On | → Overweight |
| 10/06/2022 | 295.06% | Stephens & Co. | → $16 | Initiates Coverage On | → Overweight |
| 08/17/2022 | 319.75% | Piper Sandler | $14 → $17 | Maintains | Overweight |
| 06/22/2022 | 295.06% | BTIG | → $16 | Initiates Coverage On | → Buy |
| 05/16/2022 | 245.68% | Piper Sandler | $18 → $14 | Maintains | Overweight |
| 05/09/2022 | 344.44% | Morgan Stanley | $19 → $18 | Maintains | Overweight |
| 03/18/2022 | 344.44% | Piper Sandler | $23 → $18 | Maintains | Overweight |
| 03/15/2022 | 369.14% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 02/15/2022 | 393.83% | Morgan Stanley | $24 → $20 | Maintains | Overweight |
| 05/11/2021 | 517.28% | Canaccord Genuity | → $25 | Initiates Coverage On | → Buy |
| 05/11/2021 | 467.9% | JP Morgan | → $23 | Initiates Coverage On | → Overweight |
| 05/11/2021 | 591.36% | Piper Sandler | → $28 | Initiates Coverage On | → Overweight |
| 05/11/2021 | 541.98% | Morgan Stanley | → $26 | Initiates Coverage On | → Overweight |
What is the target price for Akoya Biosciences (AKYA)?
The latest price target for Akoya Biosciences (NASDAQ: AKYA) was reported by Piper Sandler on November 13, 2023. The analyst firm set a price target for $8.00 expecting AKYA to rise to within 12 months (a possible 97.53% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akoya Biosciences (AKYA)?
The latest analyst rating for Akoya Biosciences (NASDAQ: AKYA) was provided by Piper Sandler, and Akoya Biosciences maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Akoya Biosciences (AKYA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akoya Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akoya Biosciences was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Akoya Biosciences (AKYA) correct?
While ratings are subjective and will change, the latest Akoya Biosciences (AKYA) rating was a maintained with a price target of $11.00 to $8.00. The current price Akoya Biosciences (AKYA) is trading at is $4.05, which is out of the analyst's predicted range.